In Brief: Nasacort AQ
This article was originally published in The Tan Sheet
Executive Summary
Nasacort AQ: Rhone-Poulenc Rorer prescription nasal spray approved by FDA Sept. 26 for use in children six to 11 for the treatment of nasal symptoms of seasonal and perennial allergic rhinitis. The company had submitted a supplemental NDA for children as young as four based on data from two double-blind, placebo-controlled trials involving 538 children ("The Tan Sheet" Oct. 28, 1996, In Brief). The triamcinolone acetonide nasal spray, which already carries an indication for allergy sufferers over 12, has been mentioned as an Rx-to-OTC switch candidate. An OTC version would be marketed by Novartis Consumer Health under a 1994 agreement between Rhone-Poulenc and Ciba...
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
People In Brief
Perrigo promotes in pricing, planning
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: